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BIOACTIVE PEPTIDE-BASED PROBES

the saturation of the dye or marker on the surface of the

bacteriophage and the number of bacteriophage that bind
This application claims the bene?t of US. Provisional
Patent Application Ser. No. 60/452,122, ?led Mar. 5, 2003.

With the host cell is variable. Accordingly, the use of bacte
riophages to deliver a marker to a host cell for rapid assay

purposes has not been extensively commercialized.
It is knoWn to use peptides derived from bacteriophages in
a variety of useful applications. For example, US. Pat. No.
6,297,042 for CHEESE MAKING WITH BACTERIOPH

TECHNICAL FIELD

The present invention relates to marker systems utilizing
peptides. Inparticular, the invention relates to use of bioactive

AGE RESISTANT BACTERIA, incorporated herein by ref

peptide probes labeled With desired marker molecules. The

erence, describes a method for reducing bacteriophage attack
on bacteria used in the cheese making industry. The method of

probes are useful in a number of assays, for example as part of
a rapid cell detection system. The peptides are speci?c to

the ’042 patent comprises addition of “blocker” peptides
derived by enzymatic treatment of immunoglobulins, bacte
riophages, bacteriophage parts, or mixtures thereof. Simi

receptors on bacterial cells, and may be derived from hydroly
sis of bacteriophage cells or synthetic analogs or derivatives
thereof.

larly, peptides derived by hydrolysis of Whey proteins have
been used to inhibit culture agglutination (clumping and
chaining of cells) (Ustunol, Z. and C. L. Hicks. 1994. Use of
an enzyme-treated, Whey-based medium to reduce culture
agglutination. J. Dairy Sci. 77:1479-1486; Hicks, C. L., C. E.

BACKGROUND OF THE INVENTION

Many neW rapid assays for microorganisms have been
developed during the last decade. For example, tWo of the

20

most sensitive tests on the commercial market are based on

nucleic acid probes and the Polymerase Chain Reaction
(PCR) assay. Most other tests such as radioimmunoassay and

ELISA require signi?cantly higher levels of speci?c bacteria
for enumeration. Thus, When samples With loW counts are
assayed by RIA or ELISA, an enrichment step is necessary.
Nucleic acid probes consist of DNA sequences from a
target bacteria that are used to detect homologous sequences
of bacterial DNA or RNA. Generally, the DNA of the probe

contains a radioisotope (e.g. 32P, 3H, 125I, or 14C) or other
reporter molecule. When the probe DNA hybridizes With the
bacterial DNA/RNA, hybridization can be detected. Detec

25

1998. Effect of heat treatment on immunoglobulins’ aggluti
nation response in presence of lactic cultures. J. Dairy Sci.
30

8 1 (Suppl. 1):32; both incorporated herein by reference), and
block bacteriophage adsorption and inhibit bacteriophage
proliferation (Hicks, C. L., C. E. Onuorah, andI SurjaWan.
2002. Use of hydrolyzed Whey peptides to inhibit Lactococ
cus laclis ssp. cremoris WWa phage proliferation. J. Dairy Sci.

84:Submitted; US. Pat. No. 6,297,042; both incorporated
35

herein by reference). Peptides derived from ?cin hydrolysis
of bacteriophage (q)c2) Were shoWn to inhibit groWth of Lac
lococcus laclis ssp. laclis C2 (Hicks, C. L., P. A. Clark-Safko,
I. SurjaWan, and J. O'Leary. 2004. Use of bacteriophage
derived peptides to delay phage infections. Food Res. Intl. 37

process. Thus this detection method has not been utilized by
commercial industries or medical laboratories.
PCR techniques more suited to identi?cation of microor

ganisms rather than enumeration, but detection limits may be

Tabeidie. 1998. Effect of homogenization on immunoglobu
lins’ agglutination response in presence of lactic cultures. J.

Dairy Sci. 81(Suppl. 1):32; Tabeidie, Z. and C. L. Hicks.

tion limits can be as loW as 104 cfu/g, but are best When

detecting 106 to 107 cfu/ g. Nucleic acid probe based methods
are problematic in the limited number of probes, the sample
preparation time, enrichment time, and the complexity of the

Onuorah, and I. SurjaWan. 2000. Use of hydrolyzed Whey
peptides to inhibit culture agglutination. J. Dairy Sci.
83: 1196-1202; both incorporated herein by reference), pre
vent binding of intact immunoglobulins (Hicks, C. L. and Z.

40

(2)11 15-122; incorporated herein by reference).

as loW as a single cell in puri?ed media even in a mixed

The present invention addresses the identi?ed need in the

bacterial cell population. HoWever, some compounds impede
the ampli?cation process of PCR techniques and limit the
sensitivity to greater than 104 cfu/ml. For example, PCR
hybridization has been reported to be impeded in the presence

art by providing bioactive probes comprising peptides labeled
45

With a marker. Typically, the peptides are attachment peptides
derived from bacteriophages, or are synthesized analogs or
derivatives Which correspond to such attachment peptides

of fermented solids such a cheese or Whey. Also, many PCR

and to bind to the same receptor molecules. It is knoWn that

assays require a 12 hour or overnight pre-enrichment step

attachment peptides of various bacteriophages can range
across genus (i.e. peptide sequences that bind to calcium
receptors), or can be limited to individual strains (i.e. peptide
sequences speci?c to multiple carbohydrate moieties of a

plus the time for hybridization. The complexity of the hybrid
ization step tends to limit the procedure to a sophisticated
facility such as a research laboratory. Thus the process time
and complexity of the process limits the use of this procedure

50

particular bacterial cell Wall). Thus, peptide-based probes are

by many industrial and medical laboratories.

provided, attached to a marker, Which deliver the marker to
the surface of a speci?cally targeted bacteria Where the con
centration of the marker can be quanti?ed. Further, a method

Factors that affect the commercial use of a rapid assay

include: dif?culty of sample preparation, time required to
enrich the bacteria in question, sensitivity of the assay, time
required to complete the assay, and cost. Most food and
medical rapid assays are limited by the sample preparation
time and the assays sensitivity in a “dirty” system (i.e., a
system such as a ?uid containing solids or slight turbidity).
Therefore, there is a need in the art for a rapid assay for

microorganisms for use in a relatively “dirty” system. The
rapid assay should have the features of high sensitivity and
loW preparation and assay time.
Many viruses or bacteriophages have been studied, char
acterized, and used to develop commercial antiviral products.
Fluorescent reporters or markers have been bound to bacte
riophages as an assay for host bacterial organisms. HoWever,

55

for detecting a bacteria is provided, comprising attaching a
detectable molecule to a smaller bacteriophage peptide or

synthetic bacteriophage peptide Which binds to speci?c host
bacteria, thereby increasing saturation of the marker and
improving sensitivity of the assay.
60

SUMMARY OF THE INVENTION

In accordance With the purposes of the present invention as
described herein, a method is provided for preparing a site
65

speci?c peptide probe, comprising modifying a marker to
include a tether molecule, Wherein the peptide is speci?c to a

receptor and the tether molecule is capable of covalently

US 7,759,468 B1
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binding to the peptide, and covalently binding the tether mol

FIG. 1 schematically depicts synthesis of a tether molecule

ecule to the peptide. The tether molecule may be adapted to
covalently bind to the primary amine or to the carboxyl end of
the peptide. Typically, the receptor Will be found on a surface
of a bacterial cell, such as for example the F protein receptor.

on a luminol marker for covalently binding to a peptide; and

FIGS. 2a and 2b schematically depict conjugation of a
tri-lysine peptide (2a) and a Glu-Glu peptide (2b) to the
compound of FIG. 1.
Reference Will noW be made in detail to the present pre

The peptide may include an N terminal sequence ( . . . Ala

Glu-Leu-Glu, SEQ ID NO: 1;Ala-Lys-Glu-Lys-Tyr-Val-Ile

ferred embodiment of the invention, an example of Which is

Gln-Ala-Glu-Leu-Glu, SEQ ID NO: 3) or a calcium binding

illustrated in the accompanying draWings.

sequence (Ser-Asn-Glu-Glu-Met . . . ; SEQ ID NO: 2) of the

F protein.
The peptide may be produced by hydrolysis of a bacte

DETAILED DESCRIPTION OF THE INVENTION

riophage. The bacteriophage may be selected from the group

Methods of binding/ interaction betWeen many bacteria and
bacteriophages are Well characteriZed. For example, the non

of bacteriophages speci?cally binding to Laclobacillus, Lac

pathogenic Laclococcus laclis ssp. laclis C2 host and <|>c2

Zococcus, Salmonella, Escherichia, and mixtures thereof. The
bacteriophage may be selected from the group of bacterioph

bacteriophage are one of the best characteriZed host/phage
systems in the literature (Kraus, J . and B. L. Geller. 1998.

ages speci?cally binding to Laclobacillusplanlarum species,
Laclococcus laclis species, Salmonella zyphimurium species,
Salmonella choleraesuis species, Escherichia coli species,

Membrane Receptor for prolate phages is not required for
infection of Laclococcus laclis by small or large isometric

phages. J. Dairy Sci. 81:2329-2335; Lubbers, M. W., N. R.

and mixtures thereof.

In one embodiment, the peptide is derived by hydrolyZing

20

selected from a group consisting of papain, bromelain, ?cin,
pepsin, trypsin, chymotrypsin, and mixtures thereof. In
another embodiment, the peptide may be a synthetic analog or
derivative of a bacteriophage peptide. Still further, the peptide

lactococcal bacteriophage c2 genome and identi?cation of
the structural genes. Appl. Environ. Microbiol. 6114348

4356). In particular the peptides responsible for binding of
25

the membrane of the C2 host and its corresponding gene (pip)
have been identi?ed (Kraus and Geller, 1998). This 99 kDa
membrane protein contains the receptor con?guration that the

luciferin compound, a luminol compound, and mixtures

thereof, the luciferin compound and luminol compound being
30

the marker is 6-[carboxymethoxyacetyl-N-(6-aminohexyl)
N-ethylamino]-2,3-dihydro-phthalaZine-1,4-dione or 6-[N
(6-aminohexyl)-N-ethylamino] -2,3 -dihydro -phthalaZine-1 ,
4-dione.
In another aspect of the present invention, a labeled probe

35

molecule. The peptide and marker are bound by a tether

typically speci?c to a receptor on a bacterial cell Wall. The

tether molecule may be capable of covalently binding to a
primary amine of the peptide or to a carboxyl end of the
45

EXAMPLE 1
50

A process Was developed to prepare a site-speci?c probe,
comprising modi?cation of a marker by addition of a tether

molecule capable of covalently binding to a peptide. The

described are an illustration of one of the modes best suited to

carry out the invention. It Will be realiZed that the invention is

peptide is desirably speci?c for a receptor on a surface of a
55

capable of other different embodiments and its several details
are capable of modi?cation in various, obvious aspects all
Without departing from the invention. Accordingly, the draW
ings and descriptions Will be regarded as illustrative in nature,
and not as restrictive.

molecule, Which is important in distancing the marker from
the peptide receptor to prevent steric hindrance of binding of
subsequent bioactive probes and concomitant reduction in
assay sensitivity.
The folloWing examples are presented in support of and to
further illustrate the invention as described above, but are not
to be considered as limited thereto.

In yet another aspect, the present invention provides a
method for detecting a bacterium in a complex mixture, com
prising contacting the bacterium With a labeled probe as
described above. The method is suited to a rapid assay tech
nique for bacteria in a complex mixture, such as for example
a milk or Whey preparation used in cheesemaking.
As should be appreciated, the embodiments shoWn and

of bacteria in a mixture can be developed from viral sources

vides bioactive probes comprising suchpeptides and a marker

capable of covalently binding to the peptide. The peptide is

are as described above.

<|>c2 phage binds to irreversibly. Also, the attachment protein
(protein F) of the <|>c2 phage has been identi?ed and partially
sequenced (Lubbers et al., 1995). Both the N-terminal and
calcium binding sites of the <|>c2 phage F protein have been
identi?ed (Lubbers et al., 1995). Thus, probes for rapid assay
by taking advantage of the speci?city of these attachment
proteins, and more speci?cally of the peptides speci?cally
responsible for binding. The present invention therefore pro

is provided, comprising a peptide speci?c for a receptor, the
peptide being derived from a bacteriophage or a synthetic
analog or derivative of the peptide, and a marker. As described
above, the marker is modi?ed to include a tether molecule

peptide. Other features of the peptide, marker, and receptor

many bacteriophages to bacteria have been isolated, charac

teriZed, and sequenced. As an example, the binding protein in

may be Lys-Lys-Lys, Glu-Glu, or a mixture thereof.
The marker may be selected from the group consisting of a

modi?ed to include a tether molecule. In one embodiment,

Water?eld, T. P. J . Beresford, R. W. F. LePage, and A. W.

Jarvis. 1995. Sequencing and analysis of the prolate-headed

a bacteriophage With a protease enZyme. The protease may be

target bacteria. The process is depicted schematically in FIG.
1. In this experiment, the detectable molecule Was luminol

(phthalic anhydride). Phthalic anhydride (11.7 g, 100 mmol)
60

and 6-amino hexanol (14.8 g, 100 mmol) Were admixed With
120 ml anhydrous toluene in a ?ask ?tted With Dean-Stork
apparatus and re?uxed for 12 hr. at 1200 C. The Water formed

65

rotavapor. A ?ash column chromatography Was performed
over silica gel (230-400 mesh) With ethyl acetate and petro
leum ether as eluant. The yield of the resulting 6-hydroxyl
phthaliamide compound Was 22.7 g (92%), Mp 49-500 C.

Was removed as an aZeotrope. Toluene Was removed using

BRIEF DESCRIPTION OF THE DRAWINGS

The accompanying draWings incorporated in and forming
a part of the speci?cation, illustrate several aspects of the
present invention and together With the description serve to

explain the principles of the invention. In the draWings:

To 6-hydroxyl phthaliamide (22.5 g, 0.09 mole) in 100 ml
of anhydrous toluene at 1100 C. Was added phosphorous

US 7,759,468 B1
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tribromide (17 g, 0.063 mole). The phosphorous tribromide

nol under nitrogen Was added hydrazine (5 ml, 147.1 mmol).

Was taken in 20 ml of anhydrous toluene and added slowly
through a pressure equalizing funnel. The mixture Was

The reaction mixture Was re?uxed for 3 hr under nitrogen.
The solvent Was removed under vacuum, and the solid dried
at 110° C. under vacuum. The residue Was dissolved in 10%

re?uxed for 3 hours and allowed to cool to room temperature.

The orange precipitate formed Was removed by ?ltering

HCl and ?ltered. The ?ltrate Was adjusted to pH 8 using

through celite. The ?ltrate Was then concentrated in a rotavac
to obtain an oil. The oil Was crystallized using absolute etha

potassium hydroxide. The resulting 6-[N-(6-aminohexyl)-N
ethylamino] -2,3 -dihydro -phthalazine- 1 ,4-dione precipitate

nol to yield 6-bromohexylphthalimide of analytical purity
((25.1 g (90%), Mp 59-60° C.)).

Was ?ltered and crystallized from aqueous dimethylforma
mide (DMF). Yield Was 220 mg (18%).

Next, 4-nitrophthalic acid (21.1 g, 0.1 mole) in a round
bottomed ?ask Was admixed With acetic anhydride (40 ml)

Finally,

6-[N-(6-aminohexyl)-N-ethylamino]-2,3-dihy

and re?uxed for 1 hour. The mixture Was brought to room

dro-phthalazine-l,4-dione (608 mg, 2 mmol) in 10 ml anhy

temperature and acetic anhydride Was removed under

drous DMF under nitrogen Was admixed With diglycolic

vacuum. The concentrated mixture Was alloWed to stand over

anhydride (232 mg, 2 mmol) and triethylamine (205 mg, 2

night, and the solid obtained Was recrystallized using toluene

mmol). The reaction mixture Was stirred under nitrogen for
18 hr. The solvent Was removed under vacuum and the oil

to give 4-nitrophthalic anhydride ((9.9 g (51%), Mp 119°

obtained Was dissolved in anhydrous methanol and kept at 4°

C.)).
The 4-nitrophthalic anhydride (9.5 g, 49.2 mmol) Was
combined With 20 ml of 33% methylamine solution in abso

20

4-dione Was 420 mg (50%). This product is then reacted With
the primary amine of a peptide derived from a bacteriophage,

lute ethanol in a round-bottomed ?ask and stirred for 2 hours
at 0° C. The mixture Was acidi?ed to pH 2.0 With concentrated
HCl, and concentrated under vacuum. The solid obtained Was

re?uxed With 20 ml acetic anhydride for 15 min. and alloWed
to stand overnight. The crystals obtained Were Washed With

or a synthetic analog or derivative of the peptide, to form a

?uorescently labeled peptide speci?c to the receptor of
25

acetic acid, Water, and dried. Thin layer chromatography of
the mother liquor indicated that a product Was present. The

mother liquor Was evaporated, and the resulting slurry Was
subjected to ?ash column chromatography over silica gel
(240-300 mesh) With ethyl acetate and petroleum ether as

30

(48%), Mp 177° C.

EXAMPLE 2
35

Water and 24 ml concentrated Hcl Was added N-methyl-4

To standardize the reaction conditions, the isoluminol
marker synthesized as described in Example 1 Was coupled

nitrophthalimide (4.5 g, 21.8 mmol). The mixture Was stirred
vigorously for 2 hours, and alloWed to stand overnight. The
mixture Was then concentrated to 3/4 original volume using
rotavapor. The solid obtained Was ?ltered and Washed With
Water several times. The solid Was dried to give 4-amino-N

40

6-[carboxymethoxyacetyl-N-(6-aminohexyl)-N-ethy

Next, to 6-bromohexylphthalimide (7.04 g, 22.7 mmol) in
45

added 4-amino-N-methylphthalimide (4 g, 22.7 mmol). The
mixture Was stirred under nitrogen at 120° C. for 30 hr. The
reaction mixture Was then cooled to room temperature, placed

in ice-cold Water and stirred. The resulting yelloW precipitate
Was ?ltered and recrystallized from aqueous acetic acid. Yield

With loW molecular Weight synthesized peptides. TWo pep
tides, Lys-Lys-Lys and Glu-Glu Were selected. The tri-lysine
peptide Was selected due to the availability of several amine
attachment sites. Glu-Glu Was selected due to its carboxyl
sites. Both peptides Were reacted With the reporter molecule

methylphthalimide ((2.1 g (54.7%), Mp 247-248° C.).
20 ml of anhydrous DMF under nitrogen atmosphere Was

choice. If it is desired to bind the marker to the carboxyl end
of the peptide, then the 6-[N-(6-aminohexyl)-N-ethylamino] 2,3-dihydro-phthalazine-1,4-dione is reacted With the pep
tide. The marker includes a 6 carbon tether molecule, Which
binds to the peptide, thereby providing a distance betWeen the
marker and the peptide When the peptide binds to a receptor
on a bacterial cell surface.

eluant. Yield of N-methyl-4-nitrophthalimide Was 4.9 g

To a solution of SnCl2 dihydrate (19.2 g, 85 mmol) in 8 ml

C. for crystallization. Yield of 6-[carboxymethoxyacetyl-N
(6-aminohexyl)-N-ethylamino] -2,3 -dihydro -phthalazine-1 ,

lamino]-2,3-dihydro-phthalazine-1,4-dione, prepared as
described in Example 1. Puri?ed probes Were tested using
mass spectrometry (Maldi method) and proton and carbon
nuclear magnetic resonance (NMR).

As depicted schematically in FIG. 2, the tri-lysine peptide
50

Was reacted With 6-[carboxymethoxyacetyl-N-(6-amino

of N-methyl-4-N- { 6-(N-phthalimidio)hexyl])aminophthal

hexyl)-N-ethylamino] -2,3 -dihydro -phthalazine- 1 ,4-dione in

imide Was 4.5 g (49%), Mp 169-170° C.

the presence of dicyclohexylcarbodiimide (DCC) and anhy

Next,

drous methanol at ambient temperature under nitrogen. NMR
spectra shoWed that the resulting probe Was a single posi

N-methyl-4-N- {6-(N-phthalimidio)hexyl])ami

nophthalimide (3.7 g, 9.2 mmol) Was admixed With diethyl
sulfate (11 ml, 70.84 mmol) in a ?ask under nitrogen. This

55

mixture Was gradually heated With stirring at 1 10° C. for 2 hr.
The temperature Was then raised to 160° C. and kept for 20
min. A broWn color developed. The mixture Was then cooled
to room temperature, poured into ice cold Water, and stirred.

60

The yelloW precipitate Was ?ltered and recrystallized from
aqueous acetic acid. Yield of 4-[N-ethyl-N-(6-N-phthal
imido)hexyl]amino-N-methyl phthalimide Was 2.3 g (58%),
Mp 195-196° C.

65

To 4-[N-ethyl-N-(6-N-phthalimido)hexyl]amino-N-me
thyl phthalimide (1.75 g, 4.04 mmol) in 20 ml absolute etha

tional isomer. Mass spectrometry indicated that the monomer

had a molecular Weight of 805, corresponding to the molecu
lar ion of the monoconjugated product. A small amount of
tri-lysine reacted With tWo reporter molecules (less than
0.5%), and had a molecular Weight of 1208. Although not
Wishing to be bound to any particular theory, because a single
positional isomer Was formed the reaction betWeen the tri
lysine and the reporter molecule may have occurred betWeen

the peptide primary amine and the terminal carboxyl group of
the reporter. lmportantly, successful binding of the tri-lysine
peptide to the reporter indicated that blockers on the e-amine
Were unnecessary to produce the desired bioactive probe.

US 7,759,468 B1
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EXAMPLE 3

from the F protein, from a genetically engineered source, or

synthesized commercially. The primary amine of Glu Was
then covalently bound to the carboxyl end of the tethered

The glu-glu peptide Was reacted With 6-[carboxymethoxy

acetyl-N-(6-aminohexyl)-N-ethylamino]-2,3-dihydro-ph

reporter molecule as shoWn beloW.

K

H

Ox
Ala-Lys-Glu-Lys-Tyr-Val-lle-Gln-Ala-Glu-Lue-Glu +
Amino acid sequence

\ /\/\/\/N

“W

/
HO

o

oil“

NH

0

o

6[Carboxymethoxyacetyl-N-ethylarnino]
—2 ,3 -dihydro-Phthalazine— l ,4 dione

H

K

O
NH
O
H

30

The bio-active probe produced by this procedure Was

thalaZine-l,4-dione in the presence of dicyclohexylcarbodi
imide (DCC), anhydrous methanol, and a feW drops of DMF
at 75-80° C. NMR spectra showed that the resulting probe
Was a single positional isomer. Mass spectrometry indicated
that the methylated monomer had a molecular Weight of 707.

added in excess to C2 bacteria at concentrations of 102, 103,
and 104 cfu/ml. The bio-active probe Was then alloWed to
35

suspended and Washed With phosphate dilution buffer, spun

Although not Wishing to be bound to any particular theory,
because a single positional isomer Was formed, the reaction
betWeen the Glu-Glu peptide and the reporter molecule may
have occurred betWeen the primary amine and the terminal

carboxyl group of the probe.

doWn again, and Washed a second time as before. The pellet
Was suspended in phosphate buffer and ?uorescence from the
bio-active reporter molecule Was determined using a GENios
40

PlusTM, a multi-detection microplate reader. The folloWing
data Were collected from the reader using an appropriate
blank.

The Glu-Glu peptide is knoWn to be a potent inhibitor of
groWth forL. laclis ssp. laclis C2 and other lactic acid bacteria
having calcium binding receptors on their outer membrane.

Accordingly, the bioactive Glu-Glu probe synthesized herein

absorb onto the surface of the C2 bacteria for 20 min. The
bacteria Were spun doWn (5000><g for 10 min), the pellet Was

45

Concentration of C2 bacteria

Fluorescence

is expected to bind Well to all gram positive bacteria having
104 c?J/ml
103 c?J/ml
102 c?J/ml

calcium binding receptors.
EXAMPLE 4

0.114
0.072
0.058
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This suggests that bacteria in concentrations as loW as 102

The Glu-Glu probe of Example 3 Was produced, With the
exception that the coupling reaction Was carried out in anhy

cfu/ml could be determined using this method.

drous DMF Without methanol to prevent formation of the

this invention has been presented for purposes of illustration

dimethyl ester of the coupled monoconjugated product.

The foregoing description of the preferred embodiment of
55

EXAMPLE 5

Abio-active probe highly speci?c to Laclococcus laclis ssp
laclis C2 Was provided. The N-terminal sequence of amino

60

practical application to thereby enable one of ordinary skill in
the art to utiliZe the invention in various embodiments and

acids from the c2 phage F protein are highly speci?c to the

With various modi?cations as are suited to the particular use

receptors on the outer membrane of L. Laclis ssp laclis C2.

contemplated. All such modi?cations and variations are
Within the scope of the invention as determined by the

Thus, by combining the N-terminal sequence of amino acids
from the c2 phage F protein to the marker produced as

and description. It is not intended to be exhaustive or to limit

the invention to the precise form disclosed. Obvious modi?
cations or variations are possible in light of the above teach
ings. The embodiment Was chosen and described to provide
the best illustration of the principles of the invention and its

described in Example 1, the probe is highly speci?c for the C2

appended claims When interpreted in accordance With the
breadth to Which they are fairly, legally, and equitably

laclis strain. The speci?c amino acid sequence can be derived

entitled.
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SEQUENCE LISTING

SEQ ID NO 1
LENGTH:
TYPE:

4

PRT

ORGANISM: c2 bacteriophage
<400> SEQUENCE: 1
Ala Glu Leu Glu
l

SEQ ID NO 2
LENGTH:
TYPE:

5

PRT

ORGANISM: c2 bacteriophage
<400> SEQUENCE: 2
Ser Asn Glu Glu Met
1

5

SEQ ID NO 3
LENGTH:
TYPE:

12

PRT

ORGANISM: c2 bacteriophage
<400> SEQUENCE: 3

Ala Lys Glu Lys Tyr Val Ile Gln Ala Glu Leu Glu
l

5

10

What is claimed is:

40

hydro-phthalaZine-l,4-dione marker to include an

thereof.
6. The method of claim 5, Wherein the bacteria is Lacto
45

and

hydro-phthalaZine-l ,4-dione marker to include an
50
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(SEQ ID NO: 2), Ala-Lys-Glu-Lys-Tyr-Val-Ile-Gln-Ala-Glu
Leu-Glu (SEQ ID NO: 3), Lys-Lys-Lys, or Glu-Glu.
4. The method of claim 2, Wherein the bacteriophage is
selected from the group of bacteriophages speci?cally bind

amino-terminal carboxymethoxyacetyl tether molecule;
and

bacteriophage F protein receptor.
3. The method of claim 2, Wherein the peptide consists of
Ala-Glu-Leu-Glu (SEQ ID NO: 1), Ser-Asn-Glu-Glu-Met

coccus lacZis ssp. lacZis C2.

7. A method for preparing a site-speci?c peptide probe,
Wherein the peptide is speci?c to a receptor, comprising:
modifying a 6-[N-(6-aminohexyl)-N-ethylamino]-2,3-di

amino-terminal carboxymethoxyacetyl tether molecule;
covalently binding the tether molecule to a bacteriophage
derived peptide or synthetic peptide Which binds a bac
terial surface receptor therefor.
2. The method of claim 1, Wherein the receptor is the

species, Salmonella Zyphimurium species, Salmonella chol
eraesuis species, Escherichia coli species, and mixtures

1. A method for preparing a site-speci?c peptide probe,
Wherein the peptide is speci?c to a receptor, comprising:
modifying a 6-[N-(6-aminohexyl)-N-ethylamino]-2,3-di

covalently binding the tether molecule to a bacteriophage
derived peptide Which binds a bacterial surface receptor
for a bacteriophage F protein.
8. The method of claim 7, Wherein the peptide consists of
Ala-Glu-Leu-Glu (SEQ ID NO: 1), Ser-Asn-Glu-Glu-Met

(SEQ ID NO: 2), Ala-Lys-Glu-Lys-Tyr-Val-Ile-Gln-Ala-Glu
60

Leu-Glu (SEQ ID NO: 3), Lys-Lys-Lys, or Glu-Glu.
9. The method of claim 7, Wherein the bacteriophage is
selected from the group of bacteriophages speci?cally bind

ing to Laclobacillus, Laclococcus, Salmonella, Escherichia,

ing to Laclobacillus, Laclococcus, Salmonella, Escherichia,

and mixtures thereof.

and mixtures thereof.
10. The method of claim 9, Wherein the bacteriophage is

5. The method of claim 4, Wherein the bacteriophage is
selected from the group of bacteriophages speci?cally bind
ing to Laclobacillus planlarum species, Laclococcus lacZis

65

selected from the group of bacteriophages speci?cally bind
ing to Laclobacillus planlarum species, Laclococcus lacZis

US 7,759,468 B1
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species, Salmonella zyphimurium species, Salmonella chaleraesuis species, Escherichia coli species, and mixtures
thereof.
11. The method of claim 10, Wherein the bacteria is Lac
lococcus laclis ssp. laclis C2.

5

12. A method for preparing a site-speci?c peptide probe,
Wherein the peptide is speci?c to a receptor, comprising:
modifying a 6-[N-(6-aminohexyl)-N-ethylamino]-2,3-dihydro-phthalaZine-l,4-dione marker to include an 10

covalently binding the tether molecule to a bacteriophage
derived peptide or Synthetic peptide which binds a bac
terial surface receptor therefor;
Wherein the bacteriophage-derived peptide or synthetic
peptide is selected from the group consisting ofAla-Glu
Leu'Glu (SEQ ID NO? 1), Ser-ASn-Glu-Glu-Met (SEQ
ID N01 2), Ala-Lys‘G111'Lys'Tyr-Val-He-Gln-Ala-Glu'
Leu-Glu (SEQ ID N01 3), LYS'LYS'LYS, 0r Glu-Glu

amino-terminal carboxymethoxyacetyl tether molecule;
and

*

*

*

*

*

